Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

[212Pb] VMT alpha NET - Perspective Therapeutics

Next Previous
Drug Profile

[212Pb] VMT alpha NET - Perspective Therapeutics

Alternative Names: 212Pb alpha-particle radionuclide therapy; 212Pb-VMT-α-NET; [212Pb]PSC-PEG2-TOC

Latest Information Update: 09 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Viewpoint Molecular Targeting
  • Developer Perspective Therapeutics
  • Class Antineoplastics; Lead radioisotopes; Peptides; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Neuroendocrine tumours

Most Recent Events

  • 22 Apr 2026 Updated efficacy data from a phase I/II trial in Neuroendocrine tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 08 Jan 2026 Efficacy and adverse event data from a phase I/II trial in Neuroendocrine tumours presented at the from presented at the 2026 Gastrointestinal Cancers Symposium (ASCO-GI-2026)
  • 22 Oct 2025 Updated efficacy data from a phase I/II trial in Neuroendocrine tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top